Matthew Boyd’s Post

View profile for Matthew Boyd, graphic

Chief Commercial Officer at Boyd Biomedical | Board Director | Executive Leader | Business Development

Is the transition from volume-based to value-based care good or bad for innovation? - Value-based care models, if not well-structured, can potentially limit patient choice and impede access to innovative treatments by promoting a one-size-fits-all approach to healthcare. This heads in the opposite direction of patient centric personalized care. - The shift to value-based care necessitates innovations in healthcare, requiring a focus on outcomes and patient-led solutions versus technology-led solutions. This drives us towards more real world evidence and patient engagement. New technologies are enabling more patient-centric solutions but can they survive the path to commercialization? We talk about this with Access Vascular, Inc. CEO Jim Biggins.

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics